Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Genitourinary 4Other hematologic neoplasm 3Lymphoid 2Breast 2Sarcoma 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 2Gastrointestinal Neoplasms 1Fatigue 1Cognitive Dysfunction 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Methylphenidate × Breast × Clear all
NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated
20 enrolled
Breast

Breast Neoplasms, Cognitive Dysfunction

NCT00516269 2018-01-03

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
42 enrolled 8 charts
BreastGastrointestinal

Breast Neoplasms, Fatigue, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡